News & Updates

In the prespecified interim analysis of the phase III ALIGN study, the investigational drug atrasentan shows promising signals when added to standard supportive care with a renin-angiotensin system (RAS) inhibitor in patients with IgA nephropathy (IgAN).

Increased practice of Chinese calligraphy strengthens brain network in older individuals who already practice the cognitive activity regularly and experienced subjective cognitive decline (SCD), a two-arm, parallel-design, assessor-blind, randomized controlled trial conducted by the Chinese University of Hong Kong (CUHK) has found.

Glucose-lowering drugs such as the glucagon-like peptide-1 receptor agonist (GLP-1-RA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), and dipeptidyl peptidase-4 inhibitor (DPP-4i) work better and are more cost-effective than sulfonylureas and glinides (SU) as second-line treatment for type 2 diabetes (T2D), according to a population-based retrospective cohort study.

People born in 1965 or later show signs of accelerated ageing, a phenomenon that is potentially related to the rising incidence of early-onset solid tumours worldwide, according to a large study.

Use of metoclopramide proves inadequate in enhancing endoscopic visualization among patients with overall active upper gastrointestinal bleeding (UGIB), reports a study. However, it does reduce the need for second look esophagogastroduodenoscopy (EGD).

Use of biologic mesh at the time of ileal conduit (IC) construction is safe and feasible in patients undergoing cystectomy but falls short of providing protective effects against parastomal hernia (PSH) within 2 years following surgery, reports a study.

Women with lipedema who lose weight through proper diet can see improvements in their quality of life (QoL), suggests a study. Specifically, an energy-restricted low-carbohydrate diet (LCD) appears to be better at pain reduction than a standard control diet.

In the treatment of kidney transplant recipients with antibody-mediated rejection, the CD38 monoclonal antibody felzartamab demonstrates acceptable safety and side-effect profiles as well as potential therapeutic benefit, according to a phase II trial.